Director Michael Patrick Miller filed a Form 144 notice of proposed sale of 15,000 shares of Puma Biotechnology, Inc. common stock, submitted to the SEC on November 12, 2026.
Key Highlights
- Seller: Michael Patrick Miller, identified in the filing as a Director of Puma Biotechnology, Inc.
- Shares proposed for sale: 15,000 shares of common stock, with an aggregate market value of $121,456.68.
- Approximate sale date: November 11, 2026, to be executed through Fidelity Brokerage Services LLC.
- Source of shares: Restricted stock vesting from the issuer, acquired on June 11, 2025, as compensation.
- Shares outstanding: 51,698,356 shares of common stock outstanding, according to the filing.
- Prior sales: The filing reports nothing to disclose for securities sold during the past three months.
Miller's Proposed Sale of Vested Restricted Stock at Puma Biotechnology
According to the Form 144 filed with the U.S. Securities and Exchange Commission on November 12, 2026, Michael Patrick Miller, a director of Puma Biotechnology, Inc. (NASDAQ:PBYI), intends to sell 15,000 shares of the company's common stock. The filing lists an aggregate market value of $121,456.68 for the proposed sale. The broker named in the notice is Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, Rhode Island 02917.
The filing discloses that the 15,000 shares were acquired on June 11, 2025, through a restricted stock vesting transaction from the issuer, with the nature of payment listed as compensation. The approximate date of sale is noted as November 11, 2026. The notice was signed by Daniel Tucci as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Michael Miller.
The filing states that no securities of the issuer were sold by Miller during the past three months, with the relevant section reporting nothing to disclose. Puma Biotechnology, Inc. is listed on the NASDAQ exchange and is headquartered at 10880 Wilshire Blvd., Suite 1700, Los Angeles, California 90024, according to the issuer information section of the notice.
What Was Disclosed
Puma Biotechnology director Michael Patrick Miller filed a Form 144 on November 12, 2026, proposing to sell 15,000 shares of common stock, valued at $121,456.68 in aggregate, originally acquired through restricted stock vesting as compensation on June 11, 2025.




Please wait processing your request...